Q32 Bio Inc. (QTTB): Shareholders' Equity
$42.01M
As of 2025-12-31
$105.91M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $42.01M | +640.3% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $5.67M | n/m | 2026-03-10, Balance as of period end |
| 2023-12-31 | -$182.92M | n/c | 2025-03-11, Balance as of period end |
| 2022-12-31 | $177.98M | +4.9% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $169.65M | -13.4% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $196.00M | -24.2% | 2022-03-23, Balance as of period end |
| 2019-12-31 | $258.51M | +31.7% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $196.35M | n/m | 2020-03-12, Balance as of period end |
| 2017-12-31 | -$39.45M | n/a | 2019-03-12, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $42.01M | +640.3% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $1.19B | -22.6% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $89.83M | +47.9% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $654.31M | +107.5% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $35.27M | +86.0% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $107.54M | -26.3% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$122.76M | n/m |
| Journey Medical Corp (DERM) | 2025-12-31 | $31.85M | +58.7% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $346.18M | +73.5% |
Compare QTTB, AGIO, NKTR, OCUL side by side · Screen every company in Pharmaceutical Preparations ↗